Accurate regulation of cholesterol/lipid homeostasis is essential to human health. Indeed, high circulating LDL- to-HDL ratios and elevated triglycerides are associated with metabolic syndrome, type II diabetes, and cardiovascular disease (CVD). An improved understanding of the regulatory mechanisms governing circulating levels of HDL and triglycerides could yield novel therapeutic avenues to combat cardiometabolic disorders. We recently made the surprising discovery that the human SREBP-1 and -2 genes encoding key transcriptional regulators of cholesterol/lipid biosynthesis harbor intronic microRNAs (miR-33b and miR-33a, respectively). Intriguingly, miR-33a/b represent key inhibitors of the ABCA1 cholesterol transporter and HDL synthesis to boost intracellular cholesterol levels, and injection of antisense oligonucleotides directed against miR-33a significantly increases HDL levels in mice on a western-type diet. We propose here to test the hypothesis that miR-33a/b represent central regulators of multiple aspects of mammalian cholesterol/lipid metabolism, in close cooperation with the SREBP host genes. Both in vitro cell culture and in vivo studies in mice and non-human primates will provide key mechanistic insights into the role of miR-33a/b in targeting entire pathways guiding lipid and energy homeostasis, and whether miR-33a/b may be suitable for therapeutic targeting to raise circulating HDL and lower plasma triglycerides in metabolic syndrome patients.
Low circulating high-density lipoprotein (HDL) and elevated triglycerides are associated with cardiovascular disorders, however, treatment options are limited. The proposed studies will test the hypothesis that microRNAs miR-33a/b may significantly contribute to low HDL and high triglycerides by coordinately regulating entire pathways governing cholesterol/lipid production and trafficking, in concert with their host genes, the SREBPs. Studies in mice and non-human primates will examine the feasibility of therapeutic targeting of miR- 33a/b to raise circulating HDL and lower triglycerides.
| Chery, Jessica (2016) RNA therapeutics: RNAi and antisense mechanisms and clinical applications. Postdoc J 4:35-50 |
| Goedeke, Leigh; Wagschal, Alexandre; Fernández-Hernando, Carlos et al. (2016) miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta 1861:2047-2052 |
| Wagschal, Alexandre; Najafi-Shoushtari, S Hani; Wang, Lifeng et al. (2015) Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 21:1290-7 |
| Goedeke, Leigh; Rotllan, Noemi; Canfrán-Duque, Alberto et al. (2015) MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 21:1280-9 |
| Rottiers, Veerle; Obad, Susanna; Petri, Andreas et al. (2013) Pharmacological inhibition of a microRNA family in nonhuman primates by a seed-targeting 8-mer antimiR. Sci Transl Med 5:212ra162 |
| Näär, Anders M (2013) Anti-atherosclerosis or No Anti-atherosclerosis: That is the miR-33 question. Arterioscler Thromb Vasc Biol 33:447-8 |
| Rottiers, Veerle; Näär, Anders M (2012) MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 13:239-50 |
| Rottiers, V; Najafi-Shoushtari, S H; Kristo, F et al. (2011) MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 76:225-33 |
